The results of the Turkey R&D 500 Survey, mapping the nationwide industrial research landscape, expenditures, and intellectual property (IP) assets for 13 years, have been published. Pharmaceutical exporter World Medicine demonstrated strong IP and innovation performance, securing leading spots nationwide.
According to the findings, World Medicine ranked 3rd overall with 125 registered trademarks and placed 2nd among all companies with 611 active R&D projects, reinforcing its position in high-value pharmaceutical manufacturing and technology development.
5% Turnover Allocated to R&D: Strategic Focus on Oncology and Biotech
Key operational and corporate metrics include:
R&D Reinvestment: World Medicine channels approximately 5% of its total turnover into research and innovation.
Core Therapeutic Focus: Prioritizing biotechnology and oncology pipelines to develop next-generation therapeutics.
İSO 500 Industrial Standing: Advanced to 318th place in the Istanbul Chamber of Industry’s (İSO) "Top 500 Industrial Enterprises of Turkey" survey.
Capital 500 Ranking: Positioned at 477th place within the Capital 500 index of Turkey's largest private enterprises.
Statement from Board Vice Chairman Sohrab Mammadli
Sohrab Mammadli, Vice Chairman of the Board at World Medicine, stated:
At World Medicine, we act with the vision of establishing Turkey not merely as a manufacturing center, but as a regional and global R&D, innovation, and logistics base. Ranking 3rd in the Turkey R&D 500 Survey with our 125 trademarks is a tangible indicator of the strategic priority we place on intellectual property and innovative product development. We allocate approximately 5% of our turnover to R&D, shaping future healthcare solutions through dedicated biotechnology and oncology investments. By pairing our scientific capabilities with operational agility and an expanding portfolio, we advance steadily toward becoming a global reference brand.
We integrate our R&D investments with our robust manufacturing footprint. Our standing in independent national research reflects our role among Turkey’s leading industrial enterprises. We sustained our upward trajectory in the Istanbul Chamber of Industry's İSO 500 survey, advancing to 318th place. Furthermore, our company ranked 477th in the Capital 500 list, reaffirming our sustainable financial performance.
